A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT05399654. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.
Study identification
- NCT ID
- NCT05399654
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 28, 2022 (Actual)
- Primary completion
- Jan 27, 2026 (Estimated)
- Completion
- May 19, 2026 (Estimated)
- Last update posted
- Aug 16, 2024
2022 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Southern California (USC) | Los Angeles | California | 90033 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Sarah Cannon Research Institute (SCRI)- Denver | Denver | Colorado | 80218 | — |
| AdventHealth Cancer Institute | Orlando | Florida | 32804 | — |
| Sarah Cannon Research Institute (SCRI)- Florida Cancer Specialists and Research Institute, LLC | Orlando | Florida | 32827 | — |
| John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| Weill Cornell Medicine- NYU Clinical Cancer Center | New York | New York | 10065 | — |
| West Cancer Center & Research Institute | Germantown | Tennessee | 38138 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| NEXT Oncology | Irving | Texas | 75039 | — |
| NEXT Oncology- Virginia | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05399654, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2024 · Synced Oct 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05399654 live on ClinicalTrials.gov.